Home Page

2019 Voxmedia HFSA Pgm Image

Cardiovascular, Metabolic, and Renal
Outcomes in Multi-Morbid Heart Failure
Patients with Type 2 Diabetes

Saturday,September 14, 2019

Symposium: 7:30AM - 9:30AM

Venue:  Pennsylvania Convention Center
              Room 201 A/B
              1101 Arch Street
              Philadelphia, Pennsylvania

Faculty: Javed Butler, MD, MPH, MBA(Chair);
               James Januzzi, MD; Mikhail Kosiborod, MD;
               Julie Lovshin, MD, PhD.

Registration for this program is now closed.

Note:This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Accredited Sponsor:

Program Overview:

Although diabetes and heart failure (HF) are each individually associated with considerable morbidity and mortality, they often occur together, which further worsens adverse patient outcomes, quality of life, and costs of care. Recent data from diabetes cardiovascular outcome trials (CVOTs) have underscored that HF is a critical outcome in patients with diabetes and suggest that glucose-lowering medications--sodium-glucose cotransporter 2 (SGLT2) inhibitors--may reduce the risk of HF development and progression. In addition, beneficial effects of SGLT2 inhibitors on renal outcomes have been demonstrated. HF data from CVOTs with SGLT2 inhibitors have led to the recent publication of a scientific statement from the AHA and HFSA indicating the preferred use of SGLT2 inhibitors, with the traditional agent metformin, in patients at high risk for HF and those with established HF. In this program, experts will describe the relationship between diabetes and HF, interpret HF data and renal endpoint data from clinical trials involving glucoselowering medications, describe potential mechanisms for HF and renal benefits associated with SGLT2 inhibitors, and identify ongoing clinical studies.

Educational Objectives: 
Upon completion of this activity, attendees should be able to:

  • Indicate recommendations for use of antihyperglycemic therapies for cardiovascular risk reduction in patients with T2D and atherosclerotic cardiovascular disease (ASCVD)
  • Interpret HF-related outcomes with antihyperglycemic therapies
  • Assess renal outcomes from CVOTs with antihyperglycemic therapies and emerging evidence from renal studies
  • Identify potential mechanisms for HF benefits associated with SGLT2 inhibitors

Target Audience: This educational activity is intended for cardiologists and other healthcare professionals involved in the management of patients with heart failure.

Eligibility Statement: Registration for the 23rd Annual Scientific Meeting and an official name badge are required to attend this symposium.

Privacy Policy
VOXMEDIA does not collect, use, sell or license personal information. Representations of User: By registering for this program and using the website, you hereby represent and warrant that: (i) all information contained in any information submitted by you is either owned by you or rights have been granted to you permitting you to disseminate the information as set forth in these Terms and Conditions; and (ii) the information contained in any submissions by you does not infringe on the intellectual property rights of others, including but not limited to, copyright, trademark, patent, or trade secret rights.

Accreditation and Credit Designation Statements:
Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Heart Failure Society of America designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: See onsite meeting materials for credit information. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.

Disclosure Statement:
It is the policy of Heart Failure Society of America to ensure the unbiased, fair-balanced and scientifically rigorous nature of all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial or other interest or relationship (1) with the manufacturer(s) of any commercial product(s), device(s) or service(s) AND (2) with any commercial supporters of an activity prior to participating in the planning of an activity, contributing to content, or making a presentation. Only then will faculty receive approval to participate. Faculty are expected to contribute evidence-based materials and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information is peer-reviewed.

Educational Grant: This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Americans with Disabilities Act Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 454 Morris Avenue, Springfield, New Jersey 07081 USA; Phone: 973-467-0500.